SCHEMBL2628017

SCHEMBL2628017

Cc1noc(C)c1C(C[N+](=O)[O-])c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.56
NPY2R P49146 1/20 0.50
CNR1 P21554 10/20 0.45
ALDH1A1 P00352 5/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CNR2 P34972 1/20 0.45
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
KDM4E B2RXH2 4/20 0.43
MAPT P10636 4/20 0.43
APAF1 O14727 2/20 0.43
TDP2 O95551 1/20 0.43
NPC1 O15118 2/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.41
LMNA P02545 3/20 0.41
HPGD P15428 2/20 0.41
NSD2 O96028 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2628015 0.74 GAA (0.51) GAACNR1ALDH1A1CNR2MEN1
SCHEMBL9202581 0.74 NPC1 (0.56) GAACNR1ALDH1A1CNR2MEN1
SCHEMBL2628016 0.73 KMT2A (0.47) GAACNR1ALDH1A1CNR2MEN1
SCHEMBL30220784 0.70 GAA (0.69) GAANPY2RALDH1A1L3MBTL1MEN1
SCHEMBL28607316 0.70 ALDH1A1 (0.54) GAACNR1ALDH1A1CNR2MEN1
SCHEMBL28607315 0.70 ALDH1A1 (0.54) GAACNR1ALDH1A1CNR2MEN1
SCHEMBL434045 0.66 GAA (0.45) GAANPY2RALDH1A1L3MBTL1MEN1
SCHEMBL27862778 0.66 NPC1 (0.51) CNR1CNR2MEN1KMT2AKDM4E
SCHEMBL1985442 0.66 NPC1 (0.51) CNR1CNR2MEN1KMT2AKDM4E
SCHEMBL3486501 0.66 NPC1 (0.51) CNR1CNR2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357809-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-22 US disclosed
US-8357809-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-22 US disclosed
US-20120094983-A1 ACYCLIC IKUR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-19 US disclosed
US-20120094983-A1 ACYCLIC IKUR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-19 US disclosed
US-7915410-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
US-7915410-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
US-20070082909-A1 Acyclic Ikur inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-12 US disclosed
US-20070082909-A1 Acyclic Ikur inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-12 US disclosed
WO-2007030582-A2 ACYCLIC IKUR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082909-A1 Acyclic Ikur inhibitors KCNH2, KCNJ2, KCNH3 GAA 4065/4885NPY2R 581/4885CNR1 145/4885
US-20120094983-A1 ACYCLIC IKUR INHIBITORS KCNH2, KCNJ2, KCNH3 GAA 4065/4885NPY2R 581/4885CNR1 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.